Botanix Pharmaceuticals Ltd
ASX:BOT

Watchlist Manager
Botanix Pharmaceuticals Ltd Logo
Botanix Pharmaceuticals Ltd
ASX:BOT
Watchlist
Price: 0.395 AUD 3.95% Market Closed
Market Cap: 717.9m AUD
Have any thoughts about
Botanix Pharmaceuticals Ltd?
Write Note

Botanix Pharmaceuticals Ltd
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Botanix Pharmaceuticals Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Botanix Pharmaceuticals Ltd
ASX:BOT
Free Cash Flow
-AU$26.1m
CAGR 3-Years
-106%
CAGR 5-Years
-15%
CAGR 10-Years
-35%
Recce Pharmaceuticals Ltd
ASX:RCE
Free Cash Flow
AU$3.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Free Cash Flow
-AU$36.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Free Cash Flow
AU$119.5m
CAGR 3-Years
N/A
CAGR 5-Years
117%
CAGR 10-Years
N/A
Probiotec Ltd
ASX:PBP
Free Cash Flow
AU$4.8m
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
53%
Arovella Therapeutics Ltd
ASX:ALA
Free Cash Flow
-AU$7m
CAGR 3-Years
-20%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
No Stocks Found

Botanix Pharmaceuticals Ltd
Glance View

Market Cap
715m AUD
Industry
Pharmaceuticals

Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The firm also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.

BOT Intrinsic Value
1.114 AUD
Undervaluation 65%
Intrinsic Value
Price

See Also

What is Botanix Pharmaceuticals Ltd's Free Cash Flow?
Free Cash Flow
-26.1m AUD

Based on the financial report for Jun 30, 2024, Botanix Pharmaceuticals Ltd's Free Cash Flow amounts to -26.1m AUD.

What is Botanix Pharmaceuticals Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-35%

Over the last year, the Free Cash Flow growth was -37%. The average annual Free Cash Flow growth rates for Botanix Pharmaceuticals Ltd have been -106% over the past three years , -15% over the past five years , and -35% over the past ten years .

Back to Top